HomeCompareBBNA vs ABBV

BBNA vs ABBV: Dividend Comparison 2026

BBNA yields 3.10% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $82.1K in total portfolio value
10 years
BBNA
BBNA
● Live price
3.10%
Share price
$17.75
Annual div
$0.55
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.31
Full BBNA calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BBNA vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBNAABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBNA + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BBNA pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBNA
Annual income on $10K today (after 15% tax)
$263.38/yr
After 10yr DRIP, annual income (after tax)
$0.26/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $21,055.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBNA + ABBV for your $10,000?

BBNA: 50%ABBV: 50%
100% ABBV50/50100% BBNA
Portfolio after 10yr
$61.3K
Annual income
$12,386.04/yr
Blended yield
20.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BBNA
No analyst data
Altman Z
-0.8
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBNA buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBNAABBV
Forward yield3.10%3.06%
Annual dividend / share$0.55$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$20.2K$102.3K
Annual income after 10y$0.31$24,771.77
Total dividends collected$312.00$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BBNA vs ABBV ($10,000, DRIP)

YearBBNA PortfolioBBNA Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,855$154.93$11,550$430.00$695.00ABBV
2$11,693$78.59$13,472$627.96$1.8KABBV
3$12,551$39.56$15,906$926.08$3.4KABBV
4$13,450$19.84$19,071$1,382.55$5.6KABBV
5$14,401$9.94$23,302$2,095.81$8.9KABBV
6$15,414$4.97$29,150$3,237.93$13.7KABBV
7$16,496$2.49$37,536$5,121.41$21.0KABBV
8$17,652$1.24$50,079$8,338.38$32.4KABBV
9$18,888$0.62$69,753$14,065.80$50.9KABBV
10$20,211$0.31$102,337$24,771.77$82.1KABBV

BBNA vs ABBV: Complete Analysis 2026

BBNAStock

Bonvenu Bancorp, Inc. operates as the bank holding company for Citizens National Bank that provides personal and business banking services. It offers checking, savings, and individual retirement accounts, as well as certificates of deposit. The company also provides personal loans, such as vacation loans, lines of credit, home equity loans, home construction loans, and loans for various other consumer purposes, as well as auto, boat, trailer, motorcycle, and ATV loans; and business loans, such as construction loans, real estate, industrial, small business administration, and United States Department of Agriculture loans, as well as mortgage loans. In addition, it offers investment services, including financial planning, structured products, retirement planning, education planning, estate planning, asset management, trust, small business investment, employer benefits planning, and other services; and merchant services, credit cards, and online and mobile banking services. Bonvenu Bancorp, Inc. was formerly known as Citizens National Bancshares of Bossier, Inc. and changed its name to Bonvenu Bancorp, Inc. in April 2024. Bonvenu Bancorp, Inc. was founded in 1985 and is based in Bossier City, Louisiana.

Full BBNA Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BBNA vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBNA vs SCHDBBNA vs JEPIBBNA vs OBBNA vs KOBBNA vs MAINBBNA vs JNJBBNA vs MRKBBNA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.